Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson’s Disease

By Vandana Singh
April 8, 10:11 AM
Supernus Pharmaceuticals receives FDA Complete Response Letter for SPN-830, an investigational apomorphine infusion device for Parkinson's disease. CRL indicates additional review needed for product quality and infusion device master file. No clinical safety or efficacy issues identified.

SUPN

Read More
2 minute read

Supernus Provides Regulatory Update For SPN-830, FDA Has Issued A CRL In Response To The Co’s NDA For Spn-830 Indicating That The Review Cycle For The Application Is Complete, But That The Application Is Not Ready For Approval In Its Present Form.

By Benzinga Newsdesk
April 8, 8:06 AM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update

SUPN